Natco Pharma Shares: Q3 Results, Highlights, and Performance

Natco Pharma Shares: According to February 13, 2025 then Natco Pharma’s stock has a significant decline by following the rise of its third quarter final result. According to the company report a 37.75% decrease in the net profit which made a total of Rs 132.4 crores. This happened due to primary produce formulation export the response of the stock price plunged 20% and its closing was Rs 975.05.

Apart from the rise in revenue from active pharmaceutical ingredients, the overall performance was adversely affected by the downfall in the export formulation segment. This made and accounts for 44% of total.

What is Natco Pharma?

Natco Pharma Ltd. Indian pharmaceutical company which was founded in 1981 and it’s headquartered is in Hyderabad, India. This company is specializing in production of generic drugs, oncology medicines, active pharmaceutical ingredients and contract manufacturing. It is also known for focus on making of life saving drug particularly for cancer treatment, hepatitis and cardiovascular disease.

Natco Pharma Shares Highlights.

Some key highlights of Natco Pharma Shares are as follows:

1. Stock price has dropped, failed 20% and it closed at Rs.975.05 after Q3 results.
2. There is also a deadline in net profit, as per the report Rs.132.4 crore has down by 73.75%.
3. The revenue has also been impacted where we can see major deadline due to weaker export formulation business.
4. There has been a growth in API segment their revenue from active pharmaceutical has seen active growth.

   

5. Whereas the dividend announcement has declared the third interims dividend despite the lower profits.
6. The stock is 52 weeks low which happened due to investor concerns
7. In the market segment the investors have reacted negatively, which caused High volatility.
8. whereas, the recovery depends on export performance and a new approval.

What Will Be the Future of Natco Pharma?

The current indicators suggest potential challenges ahead, Natco Pharma’s strategic initiatives in complex generics and specialty therapies may offer avenues for future growth. The investors should monitor the company’s performance in its export formulation business and its ability to bring new products to market.

Also Read This: Income Tax 2025: This year highlights, changes, important information and other details on Income Tax 2025.